Premium
Translational Nucleotide Excision Repair in Triple Negative Breast Cancer
Author(s) -
Reed Eddie
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.328.3
Subject(s) - breast cancer , triple negative breast cancer , dna repair , nucleotide excision repair , dna damage , estrogen receptor , medicine , cancer research , estrogen , progesterone receptor , oncology , immunohistochemistry , cancer , biology , dna , genetics
Triple negative breast cancer (TNBC) is generally diagnosed by immunohistochemical methods that result in negative staining for the estrogen and progesterone receptors, and human epidermal growth factor receptor 2, which are targets for the most successful treatments for breast cancer. African American women are particularly affected by the disease, and among those in this ethnic group who develop breast cancer there is a 20 to 40 percent chance of it being triple‐negative. Although the use of DNA damaging agents is standard therapy in the treatment of multiple classes of cancers, growing studies suggest that pathways that seek to repair DNA damage might also be fruitful targets. This lecture will address modulation of DNA damage and DNA repair pathways in treating TNBC, with a particular focus on nucleotide excision repair.